Safety of modern oral contraception: The options for women: Lessons to be learned

Human Reproduction Update

Volumn 5, Issue 6, 1999, Pages 633-638

  Benagiano, Giuseppe ^a   Primiero, Francesco M ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Myocardial infarction; Oral contraceptives; Pill scare; Safety of medicines; Venous thromboembolism

Indexed keywords

GESTAGEN; ORAL CONTRACEPTIVE AGENT;

DEEP VEIN THROMBOSIS; DRUG SAFETY; FEMALE; GERMANY; HUMAN; ORAL CONTRACEPTION; PREGNANCY; PREGNANCY TERMINATION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; UNITED KINGDOM;

EID: 0033373137     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/5.6.633     Document Type: Review

References (22)

1. Bloemenkamp, K.W.M., Rosendaal F.R., Helmerhost F.M. et al. (1995) Enhancement of factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet, 346, 1594-1597.
2. Committee on Safety of Medicines (1995) Combined Oral Contraceptives and Thromboembolism. Letter 17 October 1995. Committee on the Safety of Medicines, London, UK.
3. Department of Health (1999) Oral contraceptives - clearer information for women and health professionals. Press release, 7 April 1999.
4. Edwards, R.G., Beard, H.K. and Bradshaw, J.P. (1997) Balancing risks and benefits of oral contraception. Hum. Reprod., 12, 2339-2340.
5. Farley, T.M.M., Meirik, O., Chang, C.L. et al. (1995) WHO Collaborative study of cardiovascular disease and steroid hormone contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet, 346, 1582-1588.
6. Farmer, R.D.T., Lawrenson, R.A., Kennedy, J.G. and Hambleton, I.R. (1997a) Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet, 349, 83-88.
7. Farmer, R.D.T., Newson, R.B., MacRae, K. et al. (1997b) Mortality from venous thromboembolism among young women in Europe: no evidence for any effect of third generation oral contraceptives. J. Epidemiol. Commun. Health, 51, 630-635.
8. Jick, H., Jick, S.S., Gurewich, V. et al. (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components Lancet, 346, 1589-1593.
9. Lancet (1995) Sensible alert (Editorial). Lancet, 346, 1519.
10. Lancet (1997) Time to act to avoid drug safety scares (Editorial). Lancet, 350, 1041.
11. Lewis, M.A., Heinemann, L.A.J., MacRae, K.D. et al., with the Transnational Research Group on Oral Contraceptives and the Health of Young Women (1996) The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception, 54, 5-13.
12. Lewis, M.A, MacRae, K.D., Kühl-Habich, D. et al. (1999) The differential risk of oral contraceptives: the impact of full exposure history. Hum. Reprod., 14, 1493-1499.
13. Lidegaard, O. and Milsom, I. (1997) Oral contraceptives and venous thromboembolism. Lancet, 349, 1621.
14. Mellemkjaer, I., Sorensen, H.T., Dreyer, L. et al. (1999) Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark, 1977-1995. Br. Med. J., 319, 820-821.
15. Mills, A. (1997) Combined oral contraception and the risk of venous thromboembolism. Hum. Reprod., 12, 2595-2598.
16. Schering A.G. (1998) http://www.schering.de.
17. Simpson, J.-L. and Elstein, M. (1996) Safety of modern oral contraceptives. Lancet, 347, 267.
18. Spitzer, W.O. (1997) The 1995 pill scare revisited: anatomy of a non epidemic. Hum. Reprod., 12, 1347-1357.
19. Spitzer, W.O., Lewis, M.A., Heinemann, L.A.J. et al. (1996) Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br. Med. J., 312, 83-88.
20. Vandenbroucke, J.P. and Rosendaal, F.R. (1997) End of the line for 'third-generation-pill' controversy? Lancet, 349, 1113.
21. World Health Organization (1997) Scientific Group Meeting on Cardiovascular Disease and Steroid Hormone Contraceptives. Weekly Epidemiol. Rec., 48, 361-363.
22. World Health Organization (1998) Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. Technical Report Series 877, World Health Organization, Geneva, Switzerland.